|
|
|
|
Education:
Columbus State University
Columbus, GA 2001 to 2002 – Undergraduate courses
Columbia Southern University
2005 – Undergraduate courses
Troy State University
2005- Present –Business Administration |
|
|
|
Professional Experience: |
|
|
|
1997-Present |
Executive Assistant to William M. Harper IV. M.D.
Urology Center of Columbus,
LLC
Accounting (using QuickBooks) for different entities, marketing for the practice,
management team responsibilities, compliance alternate, create PowerPoint presentations
for variety of urological diseases and responsible for Dr. Harper’s schedule,
which includes: scheduling appointments, speeches and personal appointments. |
|
Oct. 2004-Present
|
Executive Director. Southeastern Medical Research Institute (SMRI)
Accounts payable, daily operations for SMRI, negotiates contracts and budgets, protocol
review and regulatory documents. Back up CRC. |
|
May 2002-Oct. 2004 |
Executive Director. Columbus Research Foundation
Accounts payable, responsible for two study coordinators, prepare budgets, protocol
review and regulatory documents. Back up study coordinator. |
|
2000-2003 |
Executive Director. Chattahoochee
Valley Urological SocietyAccounts payable, schedule-meeting
dates, acquire guest speakers, and prepare minutes for quarterly meetings. |
|
|
|
|
Credentials and Certificates: |
Microsoft Word 2000
Microsoft Outlook 2000
Microsoft Access 2000
Microsoft Excel 2000
Microsoft Outlook 2000
SAF T PAK Certificate of Training 09/30/2002-09/30/2004
CPR Certified 1998 |
|
|
|
Continuing Education |
SCR GCP Course March 7-9, 2003
Managing a Clinical Research Business (Research Dynamics) September 21-23, 2004
ACRP Annual Conference April 2005 |
|
|
|
Memberships |
|
ACRP-membership # 150256 |
|
|
|
Research: |
|
Urology-Prostate Cancer |
Protocol M97-786
Randomized Prospective Study of Adjuvant Androgen Ablation in Radical Prostatectomy
Patients at High-Risk for Disease Reoccurrence. |
Protocol: MPR-7869-001
Phase IIb, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Assess
the Safety and Efficacy of MPC-7869 in Delaying the Systemic Progression of Prostate
Cancer in Patients with Intermediate to High Risk of Recurrence with Rising PSA
Levels After Prostatectomy and Radiotherapy or Radiotherapy Alone for Localized
Disease.
Myriad Pharmaceuticals 2002. |
Protocol: TBC-PRO-002 Therion Pharmaceuticals 2003
A Phase II Randomized, Double Blind, Controlled Study to Evaluate the Safety and
Efficacy of ********/******** in Combination with GM-CSF in Patients with Androgen-Independent
Adenocarcinoma of the Prostate.
Protocol: L8891 Sanofi-Synthelabo 2004
Prospective, Observational Registry of the management of men with prostate cancer
and a rising PSA following surgical or radiological treatment of the primary tumor.
Protocol: G300203 GTX Inc. 2005
A randomized, Double-Blind, Placebo-Controlled, Multicenter Efficacy and Safety
of ***** ** for the Prevention of Bone Fractures in Men with Prostate Cancer on
Androgen Deprivation Therapy.
Protocol: 20050147 Amgen Inc. 2005
A Randomized, Double-blind, Placebo-Controlled, Multi-center Phase 3 Study of ********
on prolonging bone metastasis-free survival in men with hormone-refractory prostate
cancer.
Urology-Erectile Dysfunction
Protocol M01-293
A Phase III, Double-Blind, Randomized, Parallel Study Evaluating the Efficacy and
safety of ***** (********* tablets) Sublingual (2 and 3mg) in the Treatment of Male
Erectile Dysfunction.
Protocol MF SHIMMED
Sponsor: William M. Harper IV, MD
Minority Focused Sexual Health Inventory for Men as Model for evaluation and Detection
of Men’s Health Issues.
Protocol: M01-296.
A Phase III, 12-month, open-label, felixble dose, safety extension study of ******
tablets (2 and 3mg) in the treatment of male erectile dysfunction.
TAP Pharmaceuticals. 2002
Protocol: H6D-MC-LVFN(b)
An Open-Label Study to Evaluate the Efficacy and Safety of Tadalafil Administered
“On Demand” to Men of Various Populations with Erectile Dysfunction.
Eli Lilly 2003
Urology-Adult Growth Hormone Deficiency
Protocol CAW G/G 1991
Effects of Growth hormone (GH) or Growth Hormone Releasing Hormone (GRF) on Age-Related
Insulin resistance, pulmonary Function and Quality of Life.
Protocol: 85-036EXT. Genetech Pharmaceuticals.
National Cooperative Somatropin Surveillance (NCSS) of Nutropin AQ and Nutropin
Replacement Therapy in adults with Growth Hormone Deficiency.
Protocol: X3397n Genentech Pharmaceuticals. 2005 Independent Study
The incidence of Adult Growth Hormone Deficiency secondary to pituitary adenomas
of head trauma in hypogonadal males presenting in the urological practice.
Protocol: L3339n Genentech Pharmaceuticals. 2005
Genentech National Cooperative Metabolic Study (NCMS) of Nutropin AQ [somatropin
(rDNA origin) injection] and Nutropin [somatropin (rDNA origin) for injection] replacement
therapy in adults with growth hormone dysfunction.
Urology-Bladder Cancer
Protocol: DFMO341.
Phase III randomized, double-blind study of ***** vs. Placebo in low-grade superficial
bladder cancer.
Ilex Oncology Services. 2001
Benign Prostatis Hyperplasia(BPH)/Prostatitis
Protocol: Alfaurus EFC4428. A double-blind randomized parallel
group study of ******** 10mg OD vs Placebo in the management of acute urinary retention
in patients with a first episode due to BPH.
Sanofi-Synthelabo Research. 2001
Protocol: L8890 Sponsor- Sanofi Synthelabo 2004
Prospective, observational registry and patient survey of the management of men
with symptomatic benign Prostatic hyperplasia.
Urology-Stress Urinary Incontinence/Overactive Bladder
Protocol: F1J-US-SBCD Eli Lilly and Omnicare Pharmaceuticals 2003
Study of ********* HCI in Women of Different Demographic Characteristics and Co-morbidities
with Stress Urinary Incontinence: Evaluation of Efficacy and Safety.
Protocol: CAPSS-292 Ortho-McNeil Pharmaceuticals 2004
Randomized, Parrellel Group Trial of Ditropan XL extended release tablets or placebo
in combination with Flomax for the treatment of lower urinary symptoms.
Protocol: A6121120 Pfizer Pharmaceuticals 2005
A randomized, double-blind, placebo controlled, four arm (*****, *****, *****, and
***** plus *****) study to evaluate the clinical efficacy and safety of ***** in
men who have frequency and urgency, with or without urinary urge incontinence, with
or without bladder outlet obstruction.
Urology-Urinary Tract Infections
Protocol: CAPSS-349 Ortho-McNeil Pharmaceuticals 2005
A Study to Compare the Safety and Efficacy of Once Daily ****** versus Twice Daily
***** in the Treatment of Complicated Urinary Tract Infection and Acute Uncomplicated
Pyelonephritis.
OB/GYN-VVA
Protocol:15-50310 Hormos Medical Corporation 2006
Efficacy and safety of ******** in the treatment of vulvar and vaginal atrophy (VVA)
in postmenapausal women: A 12-week, randomized, double-blind, placebo-controlled,
parallel-group study comparing oral ***** and *** and *** daily doses with placebo. |